Severe asthma and eligibility for biologics in a Brazilian cohort
| Autor: | John H. Riley, Michelle L Kormann, Gabriela Pimentel Pinheiro, Aline Lima-Matos, L.T.M. Saturnino, Karynna P. Viana, Cinthia D Torreão, Luane Marques de Mello, Valmar Bião Lima, Claudia Soares, Alvaro A. Cruz, G. Abreu, Felipe Moraes Dos Santos, Eduardo Vieira Ponte, Evelyn Lazaridis, Divya Mohan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Severe asthma Eligibility Determination Comorbidity Severity of Illness Index Body Mass Index 03 medical and health sciences 0302 clinical medicine Sex Factors immune system diseases Internal medicine medicine Immunology and Allergy Humans 030212 general & internal medicine Anti-Asthmatic Agents Asthma Aged Biological Products business.industry Biologic therapies Age Factors Middle Aged medicine.disease respiratory tract diseases Eosinophils 030228 respiratory system Socioeconomic Factors Case-Control Studies Pediatrics Perinatology and Child Health Cohort Female Personalized medicine Inflammation Mediators business |
| Zdroj: | The Journal of asthma : official journal of the Association for the Care of Asthma. 58(7) |
| ISSN: | 1532-4303 |
| Popis: | This study aims to describe the eligibility for biologic therapies for severe asthma (SA) in a cohort of patients attending the Program for Control of Asthma (ProAR) in Bahia, Brazil.Data from SA patients (≥18 years old) attending the ProAR, that were included in a case-control study conducted from 2013 to 2015, were used to reassess patients according to a modified ERS/ATS 2014 SA criteria. Patients were then classified according to the eligibility for SA biological therapy based on current prescription labels.From 544 patients in the cohort, 531 (97.6%) were included and 172 (32.4%) were identified as SA patients according to the ERS/ATS 2014 modified criteria. Of these 172 patients, 69 (40.1%) were ineligible for any of the biologicals approved for asthma (omalizumab, mepolizumab, reslizumab and benralizumab), 60 (34.9%) patients were eligible for one of the biological therapies, and 10 (5.8%) patients were eligible for all biological therapies.More than half of patients with SA were eligible for biologic therapy in our study, but none of them received this form of treatment. Almost half of them were not eligible to any of the approved biologics, however. The variability and overlap in patients' eligibility highlight the importance of evaluating each patient individually for a more personalized treatment approach. While there is a need to increase access for some of those eligible that may really need a biologic treatment, continuous efforts are required to develop alternatives to those who are not eligible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|